Karyopharm: Putting The Phase 3 Trial In Context
Corroborated by 1 source from 1 publisher
globalcrime3h ago
TL;DR
According to seekingalpha.com, summary - Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis.